**Clostridium ramosum** rapidly identified by MALDI-TOF MS. A rare gram-variable agent of bacteraemia.

M.C. Legaria1*, S.D. García1, V. Tudanca2, C. Barberis1, L. Cipolla3, L. Cornet2, A.M.R. Famiglietti1, D. Stecher2 and C.A. Vay1

**Abstract**

*Clostridium ramosum* is an enteric anaerobic, endospore-forming, gram-positive rod with a low GC content that is rarely associated with disease in humans. We present a case of *C. ramosum* bacteraemia. To the best of our knowledge, this is the second case of *C. ramosum* bacteraemia in an elderly patient presenting with fever, abdominal pain and bilious emesis. We highlight the Gram stain variability, the lack of visualization of spores and the atypical morphology of the colonies that showed *C. ramosum* in a polymicrobial presentation that initially appeared to show monomicrobial bacteraemia. The microorganism was rapidly identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). We present a comprehensive literature review of 32 cases of clinical infections by *C. ramosum* in which we describe, if available, sex, age, clinical symptoms, predisposing conditions, other organisms present in the blood culture, other samples with *C. ramosum*, identification methodology, treatment and outcome.

**INTRODUCTION**

*Clostridium ramosum* is an anaerobic, endospore-forming and gram-positive rod that is an inhabitant of the gastrointestinal tract [1]. The organism was renamed *Erysipelatoclostridium ramosum* in 2013 [2]. Routine diagnostic laboratories may have difficulty in identifying *C. ramosum* [3].

*Clostridium* bacteraemia (CB) account for approximately 1% of all significant blood culture isolates. Most are caused by *Clostridium perfringens* [4, 5]. Occasionally, *C. ramosum* has been found in association with bacteraemia and other infections sites [6, 7].

We report a case of *C. ramosum* bacteraemia (CRB) with a devastating outcome in an elderly patient with rheumatoid arthritis who was under long-term steroid treatment, with apparent abdominal origin. The purpose of this report was:

- to alert microbiologists to suspect aerobic–anaerobic poly-microbial bacteraemia when gram-variable rods with apparent monomicrobial origin are observed in anaerobic bottles;
- to show the advantages of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for fast and reliable identification of *C. ramosum*;
- to present a literature review of bacteraemia and other clinical infections caused by *C. ramosum*.

**CASE PRESENTATION**

A patient in their 90s with a medical history of anaemia, bedridden status and rheumatoid arthritis under prednisone treatment was admitted to the emergency room with fever up 38.5 °C, bilious emesis and abdominal pain. Abdominal tenderness, diminished bowel sounds and pain at abdominal examination were observed. Heart murmurs were hypophonic. The patient was in poor general condition, with a tendency to sleep, and confused. Blood pressure was 70/40 mmHg and the respiratory rate was 30 min⁻¹. Laboratory findings showed a white blood cell count of 12×10⁹ l⁻¹ (85% neutrophils), platelets 310×10⁹ l⁻¹, glucose 66 mg dl⁻¹, urea 63 mg dl⁻¹, creatinine 1.33 mg dl⁻¹, Na⁺ 123 meq l⁻¹, K⁺ 7 meq l⁻¹, Cl⁻ 83 meq l⁻¹, aspartate aminotransferase 27 IU l⁻¹, alanine aminotransferase 10 IU l⁻¹, alkaline phosphatase 65 IU l⁻¹, total bilirubin of 1.20 mg dl⁻¹ and serum...
lactate 5.2 mmol l⁻¹. Urine and blood cultures were drawn. Because aerobic bottles were not available at that time in the emergency room, and the antimicrobial and surgical treatment had to be implemented urgently, two anaerobic bottles were collected through two venipuncture (10 ml of blood in each vial) from different sites. Piperacillin/tazobactam (4.5 g every 6 h, IV) treatment was started. Because the patient was in poor general condition, and because of the severity of the presentation, no images were taken. As bowel perforation was suspected, an exploratory laparotomy was going to be performed. Unfortunately, the patient died just before the procedure was begun. No autopsy was performed.

Urine culture was negative. Blood samples were cultured using the BD BACTEC FX system (Becton Dickinson, Franklin Lakes, NJ, USA). After a 3 h incubation period, one of the anaerobic bottles (bottle 1) became positive and Gram staining demonstrated gram-variable/negative rods. Because an aerobic subculture yielded growth of *Escherichia coli*, an anaerobic culture was not performed. After a 4 days and 7 h of incubation, the other anaerobic bottle (bottle 2) showed a thin gram-negative rod. The organism did not grow aerobically, and thus an anaerobic subculture was performed. Anaerobic growth on Brucella blood agar supplemented with hemin and vitamin K (BA) yielded a pure culture of small, greyish, smooth, round, non-haemolytic colonies with whole edges after 48 h that turned brown with longer incubation (Fig. 1). The isolate was identified as *Clostridium ramosum* by the MALDI-TOF Microflex Biotyper 3.1 with a score >2. (Bruker-Daltonics) and by conventional methods [8]. The organism stained gram-variable, although it demonstrated susceptibility to vancomycin (5 µg) and resistance to colistin (10 µg) special potency identification discs, suggesting that it was a gram-positive bacterium (Fig. 2). The isolate was nonmotile. Tests for catalase, indole, lecithinase, lipase, gelatin hydrolysis, nitrate, and the reverse CAMP test, were negative. The isolate was able to ferment maltose, glucose, sucrose, fructose, mannose, melibiose, cellobiose, raffinose, salicin, lactose and mannitol, but not arabinose and xylose. Bile esculin agar showed enhanced growth with hydrolysis of esculin.

Given that *C. ramosum* could stain as a gram-negative rod, we decided to re-examine bottle 1 under the suspicion of a polymicrobial bacteraemia. Hence, in order to find out if *C. ramosum* was present we sub-cultured it anaerobically onto BA, Brucella supplemented with vitamin K, hemin and amikacin (BAA), and BAA supplemented with vancomycin (BAAV). *C. ramosum* grew on the BA and BAA after 48 h of incubation; BA yielded *E. coli* too. Attempts to grow organisms on BAAV failed.

In order to confirm species identification, PCR amplification of the 16S rRNA was performed. The nearly complete sequence of the 16S rRNA gene was amplified by PCR with the conserved primers 8F (5′-AGAGTTTGATYMTGGCTCAG-3′) and 1942R (5′-ACCTTGTTACGACTT-3′) as described previously [9]. Cycling sequencing was performed using the Big Dye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and the ABI PRISM 3100 Genetic Analyzer (PE Applied Biosystems). The sequence obtained for the isolate analysed was assembled, manually corrected and compared to publicly available sequences in GenBank using the Basic Local Alignment Search Tool (BLAST) algorithm of the National Center for Biotechnology Information (NCBI). Alignments were performed by a hierarchical multiple alignment method implemented in the program CLUSTAL X. The sequence obtained showed 100% identity with the sequence corresponding to the 16S RNA ribosomal gene of *C. ramosum* type strain JCM 1298 (GenBank accession no. AB595128).
E. coli was susceptible to piperacillin/tazobactam. *C. ramosum* did not produce beta-lactamase [nitrocefin disc (bioMérieux)]. Antibiotic susceptibilities were determined by E-test (bioMérieux), and were interpreted using the Clinical and Laboratory Standards Institute (CLSI) M11-A8 document [10]. *C. ramosum* showed sensitivity to ampicillin (MIC 0.016 µg ml⁻¹), piperacillin/tazobactam (MIC 0.032 µg ml⁻¹), cefoxitin (MIC 4 µg ml⁻¹), metronidazole (MIC 0.094 µg ml⁻¹), imipenem (MIC 0.025 µg ml⁻¹) and clindamycin (MIC 0.075 µg ml⁻¹).

**DISCUSSION AND REVIEW OF LITERATURE**

*C. ramosum* is one of the *Clostridium* spp. that have been reported to stain gram-negative despite having a typical gram-positive cell wall [11]. In an extensive update of clostridial classification, more than 50 bacteria, previously placed in the genus *Clostridium*, have been reassigned to other taxonomic groups [12, 13]. However, many organisms still retained the *Clostridium* name, causing major confusion in clostridial taxonomy [12, 14, 15]. *C. ramosum*, a member of the cluster XVIII, along with three other *Clostridium* species, was transferred by Ludwig et al. in 2009 to the family *Erysipelotrichaceae* in the class *Erysipelotrichi* [12]. It has been proposed to assign *C. ramosum* and four related species to the new genus *Erysipelatoclostridium* [2, 15]. The microorganism was renamed *Erysipelatoclostridium ramosum* in 2013. The genus *Erysipelatoclostridium* is in the new family *Erysipelatoclostridiaceae* with other members of the XVIII clostridial cluster and was recently confirmed as a monophyletic group in a standardized revision of the taxonomy [2, 16].

The isolation and identification of *C. ramosum* in a polymicrobial presentation has some difficulties. *C. ramosum* can easily be misidentified or overlooked because it usually stains as a gram-negative rod and its terminal spores are hard to demonstrate [3, 17–19].

The Gram stain may be the oldest and most entrenched technique still in use in the microbiology laboratory. It is well recognized that certain gram-positive species often stain gram-negative or gram-variable as cultures age because of cell wall changes with loss of viability [20]. Although most *Clostridium* species are anaerobic, endospore-forming and gram-positive rods, some species may be stained gram-variable or gram-negative and their spores could be difficult to detect. Some of these microorganisms belong to the so-called ‘RIC group’: *C. ramosum*, *Clostridium innocuum* and *Clostridium clostridioforme* [3]. *C. ramosum* may be difficult to recognize in the laboratory because of its Gram stain variability and lack of spores, and the atypical clostridial morphology of its colonies [3, 17–19, 21]. It was reported that the loss of gram-positive appearance occurs most frequently in direct stains of clinical material, or in cultures after incubation for extended periods, or in species showing terminal spores [3, 22]. Therefore, *C. ramosum* can be misidentified as belonging to other genera, so the number of positive cultures is probably underestimated [23].

In our case, the organism presented as thin gram-negative rods, which made microbiological interpretation difficult. In fact, an anaerobic sub-culture was initially not carried out for bottle 1, because it was interpreted as showing monomicrobial growth, i.e. *E. coli*. Physicians and microbiologists should maintain a high level of awareness because the Gram stain of a blood culture can be misinterpreted [17, 24].

Nowadays, several commercially available identification techniques, ranging from enzyme-based systems to newer molecular PCR-based techniques (such as 16S rRNA sequencing) and MALDI-TOF MS, are in use. However, most of the kits for biochemical identification of *C. ramosum* need to be supplemented with additional tests for the complete identification of the organism [3, 18, 25, 26]. Further, ANC cards (VITEK 2, bioMérieux, France) have identified *C. ramosum* as *C. clostridioforme* [27]. For all these reasons, the 16S rRNA gene needs to be sequenced to confirm the identification [1, 9]. These factors probably lead to underreporting of this clostridial species in human infections [28].

For diagnosis and treatment purposes it is important to ensure fast and accurate identification of *Clostridium* species. The current trend is for instrumental methods to replace traditional microscopic and biochemical investigations for rapid identification. However, 16S rRNA gene sequencing is time-consuming, which may inhibit this possibly becoming a routine approach. Modern alternatives such as MALDI-TOF MS offer a fast, accurate, sensitive, robust and inexpensive solution for routine characterization and typing of microbes in laboratories. In fact, both VITEK MS (VITEK MS database 2.0, bioMérieux, France) and MALDI-TOF MS (Bruker Biotyper – Becton Dickinson) showed excellent performance for the identification of *C. ramosum* [27, 29]. However, it is important to consider which database has been used in the identification process, because in a study carried out by Lee et al., 2/7 *C. ramosum* isolates were not identified by VITEK MS with the IVD 1.1 database [30]. Fortunately, this was updated to the VITEK MS database 2.0, and interestingly 7/7 *C. ramosum* strains included in a recently published study were identified correctly [27].

CRB particularly occurs in adults predisposed to infection because of underlying malignancy and immunosuppression, and patients with bowel perforation and abscess formation [6, 31, 32], but also in immunocompetent patients [28]. CRB has comprised 0–13% of CB in published retrospective case series [4, 33]. The medical literature contains a paucity of CRB documented cases (Table 1) [6, 7, 23, 28, 31, 32, 34–42].

*C. ramosum* has been reported to cause osteomyelitis, septic arthritis, mastoiditis, spondylodiscitis, otitis media, pyelonephritis, septic arterial emboli, endocarditis, gas gangrene, septic pseudoarthrosis, peritoneal dialysis-related peritonitis, liver abscess, brain abscess, cerebellar abscess, lung abscess, Fournier’s gangrene, pseudomembranous colitis, infected thoracic aortic aneurysm and infection of intracranial hydatid cyst (Table 1) [17–19, 21, 23, 28, 34, 36, 38, 39, 43–49]. Most
| No., year reported, reference, country | Sex/age (years) | Clinical symptoms | Predisposing condition | BC/CRCB/other organisms in the BC | Others samples with C. ramosum/other microorganisms in samples with C. ramosum (except BC)/C. ramosum identification methods | Antimicrobial treatment | Outcome/BC control |
|---|---|---|---|---|---|---|---|
| 1, 1979, [47], USA | M/2 | Fever, otalgia, History of fussiness, | NR | No/– | Middle ear exudate/group A beta haemolytic streptococci/Conventional | AMP | Survived/NR |
| 2, 1983, [34], USA | M/53 | Chills, fever (38 °C), backache | Renal transplant recipient, prednisone and azathioprine treatment, bleeding duodenal ulcer, diverticular disease. | Yes/Yes/No | Left femoral artery emboli/No/nr | CLIN/PEN | Fatal/Neg |
| 3, 1988, [46], USA | F/28 | Fever (39 °C), fatigue, abdominal pain, nausea, vomiting (coffee ground emesis), melena | One week history of blunt abdominal trauma, dark urine for 1 month | Yes/No/Bacteroides fragilis Peptostreptococcus sp./nr | Perinephric abscess/Bacteroides fragilis Peptostreptococcus sp./nr | AMP +CLIN+GEN | Survived/NR (nephrectomy) |
| 4, 1991, [4], USA | F/26 | Fever (40 °C) | Colorectal tumour, necrotic tumour | Yes/Yes/Bacteroides fragilis | No/–/NR | NR | Survived/NR |
| 5, 1991, [4], USA | M/79 | Fever unknown origin, colorectal tumour | Yes/Yes/Clostridium innocuum | No/–/NR NR | No/–/nr | NR | Survived/NR |
| 6, 1995, [31], USA | F/3 | NR | Sepsis, perforated viscus | Yes/Yes/No | No/–/API anaerobic System | NR | Survived/NR |
| 7, 1995, [31], USA | M/3 | NR | Acute otitis media | No/–/– | Middle ear/No/ API anaerobic System | AMX | Survived/NR |
| 8, 1998, [19], Spain | M/59 | Fever (37.5 °C), nausea, bilious emesis, headache | HTN, alcohol abuse, generalized tonic-clonic seizure, diffuse bronchiectasis, gout | No/–/– | Brain abscess/Peptostreptococcus sp./nr | PEN | Survived/NR |
| 9, 1999, [43], The Netherlands | F/11 | Fever (40.5 °C), chills, myalgia, loss of appetite, watery bloody diarrhoea | Acute lymphatic leukaemia, mucositis, gas gangrene in the neck and thorax, chemotherapy, oral mucositis, gas gangrene in the neck and thorax | Yes/Yes/Candida albicans | No/–/Conventional | VAN+GEN+CAZ | Fatal/NR |
| 10, 2001, [21], India | M/5 | Fever 1 ½ month, irritability, headache, two previous tonic convulsions | History of bilateral chronic suppurred otitis media | No/–/– | Cerebellar abscess/No/Conventional | CHLO, MTZ, AMP | Survived/NR |
| No., year reported, reference, country | Sex/age (years) | Clinical symptoms | Predisposing condition | BC/CRBC/other organisms in the BC | Others samples with C. ramosum/other microorganisms in samples with C. ramosum (except BC)/C. ramosum identification methods | Antimicrobial treatment | Outcome/BC control |
|---------------------------------------|----------------|------------------|------------------------|---------------------------------|---------------------------------------------------------------|----------------------|------------------|
| 11, 2001, [35], USA                   | F/91           | Fever (39°C)     | HTN, DM, nursing home resident, bedridden, demented, multiple pressure sores, stage III/IV ulcer in left hip and sacrum (foul smelling discharge/necrotic/gas), osteomyelitis | Yes/Yes/No                      | No/~/API 20A                                                 | AMS+GEN              | Survived/Neg     |
| 12, 2003, [18], France                | M/74           | Afebrile, severe lower lumbar pain (6 weeks), functional incapacity | Weight loss of 9 kg, prostatic adenoma | Yes/No/No                     | Paravertebral abscess/No/API 20A (C. ramosum-Actinomyces israelii), 16S rRNA gene sequencing | AMX+ CIP, AMX+MTZ    | Survived/nr      |
| 13, 2005, [45], Turkey                | M/7            | Headache, vomiting | Intracranial hydatid cyst, Echinococcus granulosus, Pleural empyema | No/~/~                        | Cystic component/No/nr                                      | MER                  | Survived/nr      |
| 14, 2006, [36], USA                   | M/49           | Fever, weight loss | DM, Lung abscess.       | Yes/Yes/No                     |                                                               |                      |                  |
| 15, 2008, [7], USA                    | M/60           | Fever, headache  | Acute myeloid leukaemia, vesicula skin lesion on his back | Yes/Yes/No                     | No/~/~            | VAN+CAZ, AMS      | Survived/Neg     |
| 16, 2008, [38], France                | M/72           | Fever            | Aortic prosthesis, endocarditis | Yes/Yes/No                     | No/~/~/16S rRNA gene sequencing             | PTZ, AMX             | Survived/nr      |
| 17, 2012, [23], Spain                 | F/79           | Fever (39°C), abdominal pain, watery diarrhoea, weakness. | Immune competent, previous treatment with CIP and AMC, colonic ulcers | Yes/Yes/No                     | No/~/~/nr                      | MTZ                 | Survived/nr      |
| 18, 2014, [32], USA                   | F/80           | Fever (38.6°C), abdominal pain, nausea, bilious emesis | History of endometrial cancer, hysterectomy. Pancreatic adenocarcinoma, pancreatic adenocarcinoma, splenectomy, splenectomy. DM, small bowel obstruction, perforated sigmoid colon, multiple diverticula. | Yes/Yes/Bacteroides fragilis | No/~/~/nr                      | PTZ/ERT             | Fatal/Neg        |
| 19, 2015, [37], Korea                 | F/89           | Fever (38.2°C), systemic weakness | Ulcers in ankle, and coccyx | Yes/Yes/No                     | No/~/~/Vitek II ANC card (bioMérieux, Inc.), 16S rRNA gene sequencing, MALDI-TOF MS VITEK MS (bioMérieux, Inc.) | CRO, TIG             | Survived/Neg     |
| No., year reported, reference, country | Sex/age (years) | Clinical symptoms | Predisposing condition | BC/CRBC/other organisms in the BC | Others samples with C. ramosum/other microorganisms in samples with C. ramosum (except BC) | Antimicrobial treatment | Outcome/BC control |
|--------------------------------------|----------------|------------------|------------------------|----------------------------------|-------------------------------------------------------------------|-----------------------|-------------------|
| 20, 2015, [37], Korea | M/70 | Fever (38.1°C), abdominal pain | Bile duct stones, colon cancer, liver and peritoneal metastases | Yes/Yes/No | No/-/Vitek II ANC card (bioMérieux, Inc.), 16S rRNA gene sequencing, MALDI-TOF MSVITEK (bioMérieux, Inc.) | CIP, MER+TEI | Survived/nr |
| 21, 2015, [28], USA | M/26 | Low-grade fever, dull ache in the left leg, purulent drainage of the left tibia wound sinus tract | Immunocompetent, motor vehicle crash, left open tibia shaft fracture, intra medullary nailing of the tibia, locking screws, multiple debride ments and surgeries, osteomyelitis | Yes/Yes/MR Staphylococcus aureus | Surgical wound (tibia after hardware removal) /No/nr | TMP/SMX+AMS/DAP+Ert+MTZ/VAN+TIG | Survived/nr (amputation) |
| 22, 2016 [39], Spain | F/62 | 6-months of pain in her left prosthetic knee, Fever | Rheumatoid arthritis, methotrexate and prednisone treatment | Yes/No/No | Synovial fluid, intraoperative cultures (surgical debridement)/No/No | VAN+CAZ, CIP+LNZ, MER+MTZ, PEN+CL, MTZ | Fatal/NR |
| 23, 2016, [39], Spain | M/53 | Fever, pain in left hip | Osteoarthritis of the hip, prosthetic aortic valve, chronic hepatitis C infection, chronic renal failure on dialysis, abscess left wrist, girdlestone resection arthroplasty | Yes/Yes/No | Abcess left wrist, left hip intraoperative sample/No/DNA sequencing | VAN+GEN, AMP+GEN, AMC | Fatal/NR |
| 24–28 2017 [6] USA | 1-F/81 | 4/5 patients fever | Refractory acute myeloid leukemia, Pneumobilis. | Yes/Yes/Acinetobacter sp. | No/-/RapID ANA II System, Remel. 16S rRNA gene sequencing. | CEF | Fatal/NR |
| 2-F/66 | Pre-β cell acute lymphoid leukemia. Dilated common bile duct. | Yes/Yes/no | No/-/RapID ANA II System, Remel. 16S rRNA gene sequencing. | CEF+MTZ | Survived/nr |
| 3-M/79 | Acute lymphoblastic leukemia | Yes/Yes/no | No/-/RapID ANA II System, Remel. 16S rRNA gene sequencing. | CAZ+MTZ | Fatal/NR |
| 4-M/49 | Cirrhosis hepatic, encephalopathy, CDI | Yes/Yes/Citrobacter sp. | No/-/RapID ANA II System, Remel. 16S rRNA gene sequencing. | CEF | Fatal/NR |
| 5-F/83 | Refractory acute myeloid leukemia, CDI | Yes/Yes/no | No/-/RapID ANA II System, Remel. 16S rRNA gene sequencing. | CEF | Survived/nr |

Continued
| No., year reported, reference, country | Sex/age | Clinical symptoms | Predisposing condition | BC/CRCB/other organisms in the BC | Others samples with C. ramosum/other microorganisms in samples with C. ramosum (except BC)/C. ramosum identification methods | Antimicrobial treatment | Outcome/BC control |
|--------------------------------------|---------|-------------------|------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------|
| Japan 29, 2018, [44]                 | F/44    | Fever (37.4 °C), pain in the genital area (6 weeks), fatigue, loss of appetite | Central DBT insipidus, insulin-dependent DBT mellitus, frequent hospital admissions (6 weeks), under nutrition, pancreatostomy, cholecystectomy, incontinence, urinary catheter, edema of the pelvis and femoral areas | Yes/Yes/Streptococcus constellatus | no/-/16S rRNA gene sequencing | GEN,CRO,MER+CLIN+VAN | Fatal/NR |
| Switzerland 30, 2018, [17]          | M/74    | Abdominal pain, diarrhoea, confused, low blood pressure | Alcoholic liver cirrhosis, peritoneal dialysis | No/-/- | Peritoneal fluid/No/nr | CFZ+CAZ/VAN | Comfort care/NR |
| Switzerland 31, 2019, [48]          | F/26    | Pain at the right distal femur | Metastatic Ewing's sarcoma, chemotherapy, amputation, tumour resection, progressive resorption of the allograft (right distal femur) | No/-/- | Bone and allograft biopsies/No/MALDI-TOF, 16S rRNA gene sequencing | CLIN | Survived/NR |
| Japan 32, 2019, [49]                | M/73    | Upper abdominal pain, fever | Acute aortic dissection, ulcer-like projection, laryngeal nerve paralysis, diverticula in cecum and colon | Yes/No/No | Aortic wall and surrounding tissue/No/nr | MER+MTZ/MIN | Survived/NR |
| Argentina 33, present case          | N/90s   | Fever (38°C), abdominal pain, bilious emesis | HTN, rheumatoid arthritis, corticoids, chronic anaemia | Yes/Yes/Escherichia coli | no/-/MALDI-TOF, 16S rRNA gene sequencing | PTZ | Fatal/ND |

CRBC, C. ramosum in blood culture; BC, blood culture; GI, gastrointestinal tract; IV, intravenous; DM, diabetes mellitus; HTN, hypertension; nr, not reported; Neg, negative; API 20A, API 20A anaerobic strip (bioMérieux, Hazelwood, MO); ND: not drawn. PEN, penicillin; AMP, ampicillin; AMS, ampicillin sulbactam; AMX, amoxicillin; AMC, amoxicillin/clavulanic acid; GEN, gentamicin; VCN, vancomycin; PTZ, piperacillin/tazobactam; CIP, ciprofloxacin; ERT, ertapenem; MER, meropenem; TEL, teicoplanin; MTZ, metronidazole; CRO, ceftriaxone; CEF, cefepime; TIG, Tigecycline; CFZ, ceftazolin; CLIN, clindamycin; CAZ, ceftazidime; CHLO, chloramphenicol; DAP, daptomycin; TMP/SMX, trimethoprim/sulphamethoxazole; LNZ, linezolid; CDI, Clostridioides difficile infection.
C. ramosum isolates were obtained from blood culture, and occasionally from other samples, such as:

(1) Abscess in a case of cerebellar abscess secondary to otitis media in a 5-year-old boy with bilateral chronic suppurrative otitis media for 4 years for which he was being treated with no response [21].
(2) Prosthetic material in a case of septic pseudoarthrosis after an orthopaedic procedure with an allograft in a young female patient with Ewing's sarcoma [48].
(3) Peritoneal fluid in a case of peritoneal dialysis-related peritonitis. Peritoneal fluid was cultivated in a set of BacT/ALERT FAN Plus aerobic and anaerobic blood culture bottles (bioMérieux, Marcy-l’Étoile, France).

C. ramosum could be detected within 1 day in the anaerobic bottle [17].
(4) Wound in a case of osteomyelitis in an immunocompetent patient after traumatic injury [28].
(5) Perinephric abscess in a case of emphysematous pyelonephritis [46].
(6) Paravertebral abscess in a case of spondylodiscitis [18].
(7) Left femoral artery emboli in a case of endocarditis [34].
(8) Aortic wall and surrounding tissue in a case of infected thoracic aortic aneurysm [49].
(9) Middle ear in two cases of acute otitis media [31, 47].
(10) Cystic component in a case of intracranial hydatid cyst infection [45].
(11) Abscess left wrist and left hip intraoperative sample in a case of osteoarthritis of the hip [39].
(12) Abscess in a case of brain abscess [19].
(13) Synovial fluid and intraoperative samples in a case of knee prosthetic joint infection [39]. Interestingly, 11 of these 14 samples (78%) yielded C. ramosum in pure culture [17, 18, 21, 28, 31, 34, 39, 45, 48, 49].

CB frequently has a polymicrobial presentation [50]. Multiple-organism bacteraemia is a sign of intra-peritoneal sepsis [51].

C. ramosum is an inhabitant of the intestinal tract, and has only rarely been associated with severe infections [52–54]. Like other series, in our patient, we suspect an abdominal source because of the clinical and polymicrobial presentation with an enteric bacterium, i.e. E. coli [55]. Although C. ramosum is non-pathogenic, it is able to produce immunoglobulin A1 and A2 proteases, which may facilitate intestinal mucosal penetration, allowing the bacterium to escape the mucosal defense in particularly susceptible patients [53, 54, 56, 57].

Because the GC% of the gene encoding this enzyme is significantly higher than the entire genome of C. ramosum, it seems that this gene was acquired recently through horizontal gene transfer [58]. Moreover, only a fraction of the isolates are IgA protease-positive, suggesting that this enzyme is not essential to the bacterium [53] Although IgA1 is predominant in the upper respiratory tract (URT), equal proportions of IgA1 and IgA2 occur in the intestine. Most bacteria producing IgA1 protease activity colonize the URT, whereas C. ramosum is a natural inhabitant of the intestine. Therefore, possession of a proteinase cleaving both molecules seems to be beneficial for this microorganism and its in vivo fitness in the colonization of the intestine mucosa [53, 57].

On the other hand, it is interesting to note the growing importance of C. ramosum in other diseases apart from the infectious states. The gut microbiome is currently an area of intensive research. In recent studies, C. ramosum has been associated with obesity, diabetes, malignancy, enterohemorrhagic E. coli (EHEC) infection, and attention has also been paid to its use as an immunization treatment or as a biomarker for cancer [58–66].

Most reported CRB cases, like ours, occur in adults predisposed to infection because of underlying malignancy or immunosuppression, and patients with bowel perforation and abscess formation [6, 31, 32] (Table 1).

Advanced age increases the risk of clostridial infection, independent of comorbidities, which could be explained by age-related increase of clostridial species in the normal intestinal microbiota [41]. Moreover, as in our case, CRB can be associated with high mortality [6]. In one CB study, C. ramosum was among the three most highly placed isolates in the case fatality rates [41]. It is notably that 9/22 (41%) reported CRB cases had a fatal outcome [of these, 6/9 (66%) had polymicrobial bacteraemia], while 9/22 (41%) were polymicrobial. Of 31 cases of C. ramosum infections with available data, 26 (84%) presented fever. Only 1/11 patients who did not present CRB had a fatal outcome (Table 1).

The clinical significance of Clostridium isolated from blood culture is a subject of ongoing debate. Some believe this organism should never be dismissed as a contaminant [67, 68]. Others have demonstrated that Clostridium species are usually non-pathogenic [69, 70]. However, it is important to consider that microbes recovered from blood cultures should be assumed to be significant if they have established pathogenic potential or are present, as in our case, in two blood cultures [71]. Unfortunately, an anaerobic subculture was not performed for bottle 1 [E. coli and C. ramosum, time-to-positivity (TTP) 3 h] at the time it became positive. With regard to bottle 2 (C. ramosum, TTP 4 days and 7 h), a previous study demonstrated that most (85%) positive signals on days 3 to 5 were ultimately disregarded as contamination, but, late positive bottles, as in our case, can play a valuable role in the interpretation of culture, mainly if two blood cultures yielded C. ramosum [72]. Because of the patient's predisposition to a clostridial infection, the clinical presentation and outcome, and the fact that two separate blood cultures obtained from different sites (two venipuncture) were positive for C. ramosum, a rare microorganism not usually found as contaminant, we could assume that CRB in our patient was clinically significant.

On the other hand, it is important to consider that a short TTP has been reported to be an independent predictor of fatal outcome in patients with diverse-source E. coli bacteraemia [73]. Previous studies have shown that the TTP is shorter from patients whose E. coli bacteraemia are of unknown origin or non-urinary tract, from females, from cases of shock or severe sepsis, or from patients who died. Indeed, E. coli bacteraemia was an independent predictor of fatal outcome in patients with diverse-source bacteraemia [74, 75]. TTP and the clinical relevance of the individual pathogens of the polymicrobial culture cannot be determined or is difficult to determine [75]. One study...
revealed that by 48 h, 98% of aerobic gram-positive and gram-negative bloodstream infections were detected [72]. Anaerobic bacteraemia has been demonstrated to be always or frequently present in the prolonged TTP group [73, 75]. Indeed, 6/15 (40%) bloodstream infections that were detected after more than 48 h of culture incubation corresponded to anaerobes [72].

All of these facts – the negative urine culture, the short TTP (3 h) for bottle 1 (E. coli and C. ramosum) and an immunocompromised elderly patient with abdominal symptoms – led us to suspect fatal E. coli bacteraemia.

C. ramosum was susceptible to ampicillin, piperacillin/tazobactam, cefoxitin, imipenem, clindamycin and metronidazole. However, it is important to take into account that this species can produce β-lactamases and can display variable susceptibility to other antibiotics, such as penicillin, cefoxitin, quinolones, clindamycin and cephalosporins [3, 18, 41, 76–78, 28, 44]. Carbapenem resistance has also been reported [28].

Treatment of patients with C. ramosum infections should combine antimicrobial agents with an early and aggressive elimination of infectiuos foci (drainage, debridement, removal)[19, 21, 28, 32, 34, 35, 39, 344, 46, 47, 48, 49].

CONCLUSIONS

To the best of our knowledge, this is the second case of CRB in an elderly patient with fever, abdominal pain, bilious emesis and fatal outcome. We presumed an intra-abdominal source of bacteraemia, based on the clinical and the polymicrobial presentation with an intestinal inhabitant. For elderly bedridden patients with a history of rheumatoid arthritis, long-term steroid treatment and new-onset fever, CRB may be fatal with devastating consequences despite adequate surgical and medical management. However, in this patient it was not really proven that C. ramosum was the most important pathogen in the sepsis.

Its incidence is probably underestimated because Clostridium spp. observed as gram-negative thin rods is fairly uncommon and may be unrecognized from polymicrobial bacteraemia. The interpretation and meticulous observation of Gram stain and proper processing of blood cultures were very important in the bacteriological diagnosis of CRB. MALDI-TOF MS was a fast and reliable methodology for the identification of C. ramosum.

References

1. Holdeman LV, Cato EP, Moore WEC. Clostridium ramosum (Vul- lemin) comb. nov.: emended description and proposed neotype strain. Int J Syst Bacteriol 1971;21:35–39.
2. Yutin N, Galperin MY. A genomic update on clostridial phylogeny: gram-negative spore-formers and other misplaced clostridia. Environ Microbiol 2013;15:2631–2641.
3. Alexander CJ, Citron DM, Brazier JS, Goldstein EJ. Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens. J Clin Microbiol 1995;33:3209–3215.
4. Bodey GP, Rodriguez S, Fineinstein V, Elting LS. Clostridial bacteraemia in cancer patients. A 12-year experience. Cancer 1991;67:1928–1942.
5. Blairon L, De Ghelbre D, Delaere B, Sonet A, Bosly A et al. A 62-month retrospective epidemiological survey of anaerobic bacteraemia in a university hospital. Clin Microbiol Infect 2006;12:527–532.
6. Gollapudi LA, Narurkar R, Wang G, Dhand A. Clostridium ramosum (C. ramosum) bacteremia: single-center study. Open Forum Infectious Diseases 2017;4:5556.
7. Al-kali A, Oswal A, Tflyai A. Non-Autoimmune hemolytic anemia with Clostridium ramosum bacteremia. Clin Med Case Rep 2008;51–52.
8. Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML et al. Manual of clinical microbiology, 11th edition. ASM, Press, Washington DC 2015.
9. Ibrahim A, Gerner-Smidt P, Liesack W. Phylogenetic relationship of the twenty-one DNA groups of the genus Acinetobacter as revealed by 16S ribosomal DNA sequence analysis. Int J Syst Bacteriol 1997;47:837–841.
10. Clinical and Laboratory Standards Institute. MIC Testing- Performance Standards for Antimicrobial Susceptibility Testing Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, 28th Edition. Wayne, PA, USA., 2018; p. M100.
11. Freier D, Mothershed CP, Wiegel J. Characterization of Clostridium thermocellum JW20. Appl Environ Microbiol 1988;54:204–211.
12. Ludwig W, Schleifer KH, Whitman WB. Revised road map to the phylum Firmicutes. In: De Vos P, Garrity GM, Jones D, Krieg NR, Ludwig W et al. (editors). Bergey’s Manual of Systematic Bacteriology, 2, 3. New York: Springer; 2009, pp. 1–8.
13. Garrity GM, Lilburn TG, Cole JR, Harrison SH, Euzéby J et al. The Bacteria: phylum Firmicutes: class Clostridia. In: Garrity GM (editor). The taxonomic outline of Bacteria and Archaea. Michigan State University; 2007. pp. 271–316.
14. Rainey FA. Family X. Veillonellaceae. In: De Vos P, Garrity GM, Jones D, Krieg NR, Ludwig W et al. (editors). Bergey’s Manual of Systematic Bacteriology, 2, 3. New York: Springer; 2009, pp. 1059–1129.
15. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ et al. An improved Greengenes taxonomy with explicit ranks for ecolog- ical and evolutionary analyses of bacteria and archaea. ISME J 2012;6:610–618.
16. Parks DH, Chuvochina M, Waite DW, Rinke C, Skarshewski A et al. A standardized bacterial taxonomy based on genome phylogeny substantially revises the tree of life. Nat Biotechnol 2018;36:996–1004.
17. Gerber JS, Berney-Meyer L, Segerer S. Clostridium Ramusum — A Rare Cause of Peritoneal Dialysis-Related Peritonitis. Perit Dial Int 2018;38:231–232.
18. Lavigne J-P, Bouziges N, Sotto A, Leroux J-L, Michaux-Charachon S, Charachon SM. Spondylodiscitis due to Clostridium ramusum infection in an immunocompetent elderly patient. J Clin Microbiol 2003;41:2223–2226.
19. Miret C, Fernandez-Sola J, Molleda M, De Dios A. Clostridium ramusum: a rare cause of brain abscess. An Med Intern 1998;15:392–393.
20. Beveridge TJ. Mechanism of gram variability in select bacteria. J Bacteriol 1990;172:1609–1620.
21. Set R, Kandian S, Kopikar GV. Clostridium ramosum in a case of cerebellar abscess. Médicine et maladies infectieuses 2008;38:5145–5147E-08.
22. Brookes I. Antimicrobe. Clostridium species (Clostridium perfringens, C. butyricum, C. clostridiiforme, C. innocuum, C. ramosum, C. septicum, C. sordellii, C. tertium). http://www.antimicrobe.org/b90.asp, 2016-antimicrobe.org.
23. Alcalde-Vargas A, Trigo-Salado C, Leo-Carnerero E, Cruz-Ramirez Dde-la, Herrera-Justiniano JM. Pseudomembranous colitis and bacteremia in an immunocompetent patient associated with a rare specie of Clostridium (C. ramosum). Rev Esp Enferm Diag 2012;104:498–499.
24. Rand KH, Tillian M. Errors in interpretation of gram stains from positive blood cultures. Am J Clin Pathol 2006;126:686–690.
25. Kim YJ, Kim SH, Park H-J, Park H-G, Park D et al. Maldi-Tof MS is more accurate than Vitek II ANC card and API rapid ID 32 a system for the identification of Clostridium species. Anaerobe 2016;40:73–75.
26. Lee EHL, Degener JE, Welling GW, Veloo ACM. Evaluation of the Vitek 2 ANC card for identification of clinical isolates of anaerobic bacteria. J Clin Microbiol 2011;49:1745–1749.
27. Tsukimoto ER, Rossi F. Evaluation of MALDI-TOF mass spectrometry (VITEK-MS) compared to the ANC card (Vitek 2) for the identification of clinically significant anaerobes. J Bras Patol Med Lab 2015;51:206–212.
28. Dahya V, Ramgopal M, Collin B, Robinson M. Clostridium ramosum osteomyelitis in an immunocompetent patient after traumatic injury. Infect Dis Clin Pract 2015;23:102–104.
29. Nagy E, Becker S, Kostrzewa M, Barta N, Urbán E. The value of MALDI-TOF MS for the identification of clinically relevant anaerobic bacteria in routine laboratories. J Med Microbiol 2012;61:1393–1400.
30. Lee W, Kim M, Yong D, Jeong SH, Lee K et al. Evaluation of Vitek mass spectrometry (MS), a matrix-assisted laser desorption ionization time-of-flight MS system for identification of anaerobic bacteria. Ann Lab Med 2015;35:69–75.
31. Brook I. Clostridial infection in children. J Med Microbiol 1995;42:78–82.
32. Forrester JD, Spain DA. Clostridium ramosum bacteremia: case report and literature review. Surg Infect 2014;15:343–346.
33. Shah M, Bishburg E, Baran DA, Chan T. Epidemiology and outcomes of clostridial bacteremia at a tertiary-care institution. The Scientific World Journal 2009;9:144–148.
34. Musakkassia WF, Mohanty PK, Kipreous B. Left ventricular mass with septic (Clostridium ramosum) arterial emboli in a renal allograft patient: Report of a case and review of the literature. Transplant Proc 1993;15:1715–1719.
35. Mohandas R, Poduval RD, Unnikrishnan D, Corpuz M. Clostridium ramosum bacteremia and osteomyelitis in a patient with infected pressure sores. Infect Dis Clin Pract 2001;10:123–124.
36. Nanda V, Noskuhl GW. Lung abscess caused by Clostridium ramosum. J Okla State Med Assoc 2006;99:158–160.
37. Lim YK, Oh SM, Kweon OJ, Lee M-K. Two cases of bacteremias caused by Listeria ramosum. Ann Clin Microbiol 2015;18:98–101.
38. Lorieach A, Cazanave C, Pereyre S, Kuli B. Neau D et al. Une endocardite Clostridium ramosum; premier cas décrit ?Hospitalier Pellegrin, Médecine et maladies infectieuses 2008;38:5145–5147E-08.
39. García-Jiménez A, Prim N, Crusi X, Benito N. Septic arthritis due to Clostridium ramosum. Semin Arthritis Rheum 2016;45:617–620.
40. Hammond SP, Buckley MW, Petruzzello G, Koo S, Marty FM et al. Clinical characteristics and outcomes of clostridial bacteremia in cancer patients. Clin Microbiol Infect 2014;20:752–757.
41. Leal J, Gregson DB, Ross T, Church DL, Laupland KB. Epidemiology of Clostridium species bacteremia in Canada, 2000–2006. J. Infection 2008;57:198–202.
42. Lombardi DP, Engleberg NC. Anaerobic bacteremia: incidence, patient characteristics, and clinical significance. Am J Med 1992;92:53–60.
43. van der Vorm ER, von Rosenstiel IA, Spanjaard L, Dankert J. Gas gangrene in an immunocompromised girl due to a Clostridium ramosum infection. Clin Infect Dis 1999;29:923–924.
44. Takano N, Yatabe MS, Yatabe J, Kato M, Sueoka D et al. Fatal Fournier’s gangrene caused by Clostridium ramosum in a patient with central diabetes insipidus and insulin-dependent diabetes mellitus: a case report. BMC Infect Dis 2018;18:363.
45. Turkoğlu OF, Solaroglu I, Tun K, Beskonaklı E, Taskın Y. Secondary infection of intracranial hydatid cyst with Clostridium ramosum. J Childs Nerv Syst 2005;21:1004–1007.
46. Langdale LA, Rice CL, Brown N. Empysematous pyelonephritis in a xanthogranulomatous kidney. An unusual cause of pneumoperitoneum. Arch. Surg. 1988;123:377–379.
47. Brook I, Schwartz RH, Controni G. Clostridium ramosum bacteremia and beta hemolytic streptococci isolated from a child presenting with acute otitis media. Clin Pediatr 1979;18:699–700.
48. Zakhari F, Pillonel T, Brunel A-S, Zambelli P-Y, Greub G et al. Molecular diagnosis and enrichment culture identified a septic pseudoanaerobiosis due to an infection with Erysipelatoclostridium ramosum. Int J Infect Dis 2019;81:167–169.
49. Kozaki S, Miyamoto S, Uchida K, Shuto T, Tanaka H et al. Infected thoracic aortic aneurysm caused by Clostridium ramosum: a case report. J Cardiol Cases 2019;20:103–105.
50. Ingram CW, Cooper JN. Clostridial bloodstream infections. South Med J 1989;82:29–31.
51. Ing AF, McLean AP, Meakins JL. Multiple-organism bacteremia in the surgical intensive care unit: a sign of intraperitoneal sepsis. Surgery 1981;90:779–786.
52. De Keuleleire S, Wybo I, Naessens A, Echahidi F, Van de Beken M et al. Anaerobic bacteremia: a 10-year retrospective epidemiological survey. Anaerobe 2016;39:54–59.
53. Senda S, Fujiyama Y, Ushijima T, Hodohara K, Bamba T et al. Clostridium ramosum, an IgA protease-producing species and its ecology in the human intestinal tract. Microbiol Immunol 1985;29:1019–1028.
54. Attebery HR, Sutter VL. Finegold SM. Normal human intestinal flora. Anaerobic Bacteria: Role in Disease. Springfield: IL, Charles C Thomas Co; 1974. pp. 81–97.
55. Rechner PM, Agger WA, Mruz K, Coghill TB. Clinical features of clostridial bacteremia: a review from a rural area. Clin Infect Dis 2001;33:349–353.
56. Kosowska K, Reinholdt J, Rasmussen LK, Sabat A, Potempa J et al. The Clostridium ramosum IgA Protease Represents a Novel Type of Metalloendopeptidase. J Biol Chem 2002;277:11987–11994.
57. Mehta SK, Plaut AG, Calvanico NJ, Tomas TB, AG Plaut. Human immunoglobulin A: production of an Fc fragment by an enteric microbial proteolytic enzyme. J Immunol 1973;111:1274–1276.
58. Potempa J, Poulsen KB,Barrett AJ, Rawlings ND, Woessner JF (editors). IgA protease of Clostridium ramosum. Handbook of Proteolytic Enzymes, 2 ed. London: Elsevier, Academic Press; 2004. pp. 759–762.
59. Voting A, Pleiffer N, Loh G, Klaus S, Blaut M. Clostridium ramosum promotes high-fat diet-induced obesity in gnotobiotic mouse models. MBio 2014;5:01530–01514.
60. Mandic AD, Voting A, Jaenicke T, Sander A, Sabrowski W et al. Clostridium ramosum regulates enterochromaffin cell development and serotonin release. Sci Rep 2019;4:1177.
61. Fujimoto K, Kawaguchi Y, Shimohigashi M, Gotoh Y, Nakano Y et al. Antigen-Specific mucosal immunity regulates development of intestinal bacteria mediated diseases. Gastroenterology 2019;157:1530–1543.
62. Fujimoto K, Uematsu S. Development of prime-boost-type next-generation mucosal vaccines. Int Immunol 2019;pii: dxz085.
63. Liang Q, Chiu J, Chen Y, Huang Y, Higashimori A et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin Cancer Res 2017;23:2061–2070.

64. Yu J, Feng Q, Wong SH, Zhang D, Liang QY et al. Metagenomic analysis of fecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 2017;66:70–78.

65. Jiang H, Li J, Zhang B, Huang R, Zhang J et al. Intestinal flora disruption and novel biomarkers associated with nasopharyngeal carcinoma. Front Oncol 2019;6:1346.

66. Koyanagi Y, Suzuki R, Ihara K, Miyagi H, Isogai H et al. Intestinal Clostridium species lower host susceptibility to enterohemorrhagic Escherichia coli O157:H7 infection. Pathog Dis 2019;77:ftz036.

67. Xu J, Koyanagi Y, Isogai E, Nakamura S. Effects of fermentation products of the commensal bacterium Clostridium ramosum on motility, intracellular pH, and flagellar synthesis of enterohemorrhagic Escherichia coli. Arch Microbiol 2019;201:841–846.

68. Benjamin B, Kan M, Schwartz D, Siegman-Igra Y. The possible significance of Clostridium spp. in blood cultures. Clin Microbiol Infect 2006;12:1006–1012.

69. Chen YM, Lee HC, Chang CM, Chuang YC, Ko WC. Clostridium bacteremia: emphasis on the poor prognosis in cirrhotic patients. J Microbiol Immunol Infect 2001;34:113–118.

70. Weinstein MP, Reller LB, Murphy JR, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. laboratory and epidemiologic observations. Rev Infect Dis 1983;5:35–53.

71. Gorbach SL, Thadepalli H. Isolation of Clostridium in human infections: evaluation of 114 cases. J Infect Dis 1975;131:S81–S85.

72. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection Society and the infectious diseases Society of America. Clin Infect Dis 2010;50:133–164.

73. Pardo J, Klinker KP, Borgert SJ, Trikha G, Rand KH et al. Time to positivity of blood cultures supports antibiotic de-escalation at 48 hours. Ann Pharmacother 2014;48:33–40.

74. Martinez JA, Soto S, Fabrega A, Almeia M, Mensa J et al. Relationship of phylogenetic background, biofilm production, and time to detection of growth in blood culture vials with clinical variables and prognosis associated with Escherichia coli bacteremia. J Clin Microbiol 2006;44:1468–1474.

75. Peralta G, Roiz MP, Sánchez MB, Garrido JC, Ceballos B et al. Time-to-positivity in patients with Escherichia coli bacteraemia. Clin Microbiol Infect 2007;13:1077–1082.

76. Lambregts MMC, Bernards AT, van der Beek MT, Visser LG, de Boer MG. Time to positivity of blood cultures supports early re-evaluation of empiric broad-spectrum antimicrobial therapy. PLoS One 2019;14:0208819.

77. Nord CE, Hedberg M. Resistance to β-lactam antibiotics in anaerobic bacteria. Rev Infect Dis 1990;12:5231–5234.

78. Tally FP, Armfield AV, Dowell VR, Kwok Y-Y, Sutter VL et al. Susceptibility of Clostridium ramosum to antimicrobial agents. Antimicrob Agents Chemother 1974;9:589–593.

---

**Five reasons to publish your next article with a Microbiology Society journal**

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.